Tumour suppressor p53 down-regulates the expression of the human hepatocyte nuclear factor 4α (HNF4α) gene

Biochemical Journal

Volumn 400, Issue 2, 2006, Pages 303-313

  Maeda, Yutaka ^a,c   Hwang Verslues, Wendy W ^a   Wei, Gang ^b,d   Fukazawa, Takuya ^b,e   Durbin, Mary L ^a,f   Owen, Laurie B ^b,g   Liu, Xuan ^b   Sladek, Frances M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^e OKAYAMA UNIVERSITY   (Japan)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g BIOLEGEND   (United States)

Author keywords

Doxorubicin; Hepatocyte nuclear factor 4 (HNF4 ); Hepatocyte nuclear factor 6 (HNF6); Nuclear receptor; p53

Indexed keywords

CELL CULTURE; DNA; GENES; PRECIPITATION (CHEMICAL); TOXIC MATERIALS; TUMORS;

DOXORUBICIN; HEPATOCYTE NUCLEAR FACTOR 6 (HNF6); IMMUNOPRECIPITATION; NUCLEAR RECEPTORS;

PROTEINS;

CELL NUCLEUS RECEPTOR; DOXORUBICIN; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HEPATOCYTE NUCLEAR FACTOR 6ALPHA; MESSENGER RNA; PROTEIN P53; TRANSCRIPTION FACTOR; TRICHOSTATIN A; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA BINDING; DRUG INHIBITION; GENE CONTROL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; ULTRAVIOLET IRRADIATION;

ADENOVIRIDAE; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOWN-REGULATION; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE NUCLEAR FACTOR 4; HEPATOCYTE NUCLEAR FACTOR 6; HISTONE DEACETYLASES; HUMANS; LIVER NEOPLASMS; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; TRANS-ACTIVATION (GENETICS); TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; ULTRAVIOLET RAYS;

EID: 33845230349     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20060614     Document Type: Article

References (57)

1. Bargonetti, J. and Manfredi, J. J. (2002) Multiple roles of the tumor suppressor p53. Curr. Opin. Oncol. 14, 86-91
2. Esteve, P. O., Chin, H. G. and Pradhan, S. (2005) Human maintenance DNA (cytosine-5)-methyltransferase and p53 modulate expression of p53-repressed promoters. Proc. Natl. Acad. Sci. U.S.A. 102, 1000-1005
3. Ho, J. and Benchimol, S. (2003) Transcriptional repression mediated by the p53 tumour suppressor. Cell Death Differ. 10, 404-408
4. Ko, L. J. and Prives, C. (1996) p53: puzzle and paradigm. Genes Dev. 10, 1054-1072
5. Mirza, A., Wu, Q., Wang, L., McClanahan, T., Bishop, W. R., Gheyas, F., Ding, W., Hutchins, B., Hockenberry, T., Kirschmeier, P. et al. (2003) Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Oncogene 22, 3645-3654
6. Murphy, M., Ahn, J., Walker, K. K., Hoffman, W. H., Evans, R. M., Levine, A. J. and George, D. L. (1999) Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. 13, 2490-2501
7. Liu, G., Schwartz, J. A. and Brooks, S. C. (1999) p53 down-regulates ER-responsive genes by interfering with the binding of ER to ERE. Biochem. Biophys. Res. Commun. 264, 359-364
8. Maiyar, A. C., Phu, P. T., Huang, A. J. and Firestone, G. L. (1997) Repression of glucocorticoid receptor transactivation and DNA binding of a glucocorticoid response element within the serum/glucocorticoid-inducible protein kinase (sgk) gene promoter by the p53 tumor suppressor protein. Mol. Endocrinol. 11, 312-329
9. Yap, N., Yu, C. L. and Cheng, S. Y. (1996) Modulation of the transcriptional activity of thyroid hormone receptors by the tumor suppressor p53. Proc. Natl. Acad. Sci. U.S.A. 93, 4273-4277
10. Maeda, Y., Seidel, S. D., Wei, G., Liu, X. and Sladek, F. M. (2002) Repression of hepatocyte nuclear factor 4α tumor suppressor p53: involvement of the ligand-binding domain and histone deacetylase activity. Mol. Endocrinol. 16, 402-410
11. Sladek, F. M. and Seidel, S. D. (2001) Hepatocyte Nuclear Factor 4α. In Nuclear Receptors and Genetic Diseases (Burris, T. P. and McCabe, E. R. B., eds.), pp. 309-361, Academic Press, London
12. Darlington, G. J. (1999) Molecular mechanisms of liver development and differentiation. Curr. Opin. Cell Biol. 11, 678-682
13. Zaret, K. S. (2002) Regulatory phases of early liver development: paradigms of organogenesis. Nat. Rev. Genet. 3, 499-512
14. Zhao, R. and Duncan, S. A. (2005) Embryonic development of the liver. Hepatology 41, 956-967
15. Ryffel, G. U. (2001) Mutations in the human genes encoding the transcription factors of the hepatocyte nuclear factor (HNF)1 and HNF4 families: functional and pathological consequences. J. Mol. Endocrinol. 27, 11-29
16. Briancon, N., Bailly, A., Clotman, F., Jacquemin, P., Lemaigre, F. P. and Weiss, M. C. (2004) Expression of the α7 isoform of hepatocyte nuclear factor (HNF) 4 is activated by HNF6/OC-2 and HNF1 and repressed by HNF4α1 in the liver. J. Biol. Chem. 279, 33398-33408
17. Eeckhoute, J., Moerman, E., Bouckenooghe, T., Lukoviak, B., Pattou, F., Formstecher, P., Kerr-Conte, J., Vandewalle, B. and Laine, B. (2003) Hepatocyte nuclear factor 4α isoforms originated from the P1 promoter are expressed in human pancreatic β-cells and exhibit stronger transcriptional potentials than P2 promoter-driven isoforms. Endocrinology 144, 1686-1694
18. Tanaka, T., Jiang, S., Hotta, H., Takano, K., Iwanari, H., Sumi, K., Daigo, K., Ohashi, R., Sugai, M., Ikegame, C. et al. (2006) Dysregulated expression of P1 and P2 promoter-driven hepatocyte nuclear factor-4α in the pathogenesis of human cancer. J. Pathol. 208, 662-672
19. Torres-Padilla, M. E., Fougere-Deschatrette, C. and Weiss, M. C. (2001) Expression of HNF4α isoforms in mouse liver development is regulated by sequential promoter usage and constitutive 3′ end splicing. Mech. Dev. 109, 183-193
20. Hatzis, P. and Talianidis, I. (2001) Regulatory mechanisms controlling human hepatocyte nuclear factor 4α gene expression. Mol. Cell Biol. 21, 7320-7330
21. Hatzis, P. and Talianidis, I. (2002) Dynamics of enhancer-promoter communication during differentiation-induced gene activation. Mol. Cell 10, 1467-1477
22. Lannoy, V. J., Burglin, T. R., Rousseau, G. G. and Lemaigre, F. P. (1998) Isoforms of hepatocyte nuclear factor-6 differ in DNA-binding properties, contain a bifunctional homeodomain, and define the new ONECUT class of homeodomain proteins. J. Biol. Chem. 273, 13552-13562
23. Lannoy, V. J., Rodolosse, A., Pierreux, C. E., Rousseau, G. G. and Lemaigre, F. P. (2000) Transcriptional stimulation by hepatocyte nuclear factor-6. Target-specific recruitment of either CREB-binding protein (CBP) or p300/CBP-associated factor (p/CAF). J. Biol. Chem. 275, 22098-22103
24. Sladek, F. M., Zhong, W. M., Lai, E. and Darnell, Jr, J. E. (1990) Liver-enriched transcription factor HNF4 is a novel member of the steroid hormone receptor superfamily. Genes Dev. 4, 2353-2365
25. Wang, B., Cai, S. R., Gao, C., Sladek, F. M. and Ponder, K. P. (2001) Lipopolysaccharide results in a marked decrease in hepatocyte nuclear factor 4 α in rat liver. Hepatology 34, 979-989
26. Zhang, W. W., Fang, X., Mazur, W., French, B. A., Georges, R. N. and Roth, J. A. (1994) High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther. 1, 5-13
27. Jiang, G., Nepomuceno, L., Hopkins, K. and Sladek, F. M. (1995) Exclusive homodimerization of the orphan receptor hepatocyte nuclear factor 4 defines a new subclass of nuclear receptors. Mol. Cell Biol. 15, 5131-5143
28. Nie, Y., Li, H. H., Bula, C. M. and Liu, X. (2000) Stimulation of p53 DNA binding by c-Abl requires the p53 C-terminus and tetramerization. Mol. Cell Biol. 20, 741-748
29. Yew, P. R., Liu, X. and Berk, A. J. (1994) Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53. Genes Dev. 8, 190-202
30. Liu, X., Miller, C. W., Koeffler, P. H. and Berk, A. J. (1993) The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription. Mol. Cell Biol. 13, 3291-3300
31. Maeda, Y., Rachez, C., Hawel, 3rd, L., Byus, C. V., Freedman, L. P. and Sladek, F. M. (2002) Polyamines modulate the interaction between nuclear receptors and vitamin D receptor-interacting protein 205. Mol. Endocrinol. 16, 1502-1510
32. Lee, T. K., Lau, T. C. and Ng, I. O. (2002) Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines. Cancer Chemother. Pharmacol. 49, 78-86
33. Jiang, G., Nepomuceno, L., Yang, Q. and Sladek, F. M. (1997) Serine/threonine phosphorylation of orphan receptor hepatocyte nuclear factor 4. Arch. Biochem. Biophys. 340, 1-9
34. Lahuna, O., Rastegar, M., Maiter, D., Thissen, J. P., Lemaigre, F. P. and Rousseau, G. G. (2000) Involvement of STAT5 (signal transducer and activator of transcription 5) and HNF4 (hepatocyte nuclear factor 4) in the transcriptional control of the hnf6 gene by growth hormone. Mol. Endocrinol. 14, 285-294
35. Guimaraes, D. P. and Hainaut, P (2002) TP53: a key gene in human cancer. Biochimie 84, 83-93
36. Bullock, A. N. and Fersht, A. R. (2001) Rescuing the function of mutant p53. Nat. Rev. Cancer 1, 68-76
37. Hearnes, J. M., Mays, D. J., Schavolt, K. L., Tang, L., Jiang, X. and Pietenpol, J. A. (2005) Chromatin immunoprecipitation-based screen to identify functional genomic binding sites for sequence-specific transactivators. Mol. Cell Biol. 25, 10148-10158
38. Innocente, S. A. and Lee, J. M. (2005) p53 is a NF-Y- and p21-independent, Sp1-dependent repressor of cyclin B1 transcription. FEBS Lett. 579, 1001-1007
39. Crighton, D., Woiwode, A., Zhang, C., Mandavia, N., Morton, J. P., Warnock, L. J., Milner, J., White, R. J. and Johnson, D. L. (2003) p53 represses RNA polymerase III transcription by targeting TBP and inhibiting promoter occupancy by TFIIIB. Embo J. 22, 2810-2820
40. Farmer, G., Friedlander, P., Colgan, J., Manley, J. L. and Prives, C. (1996) Transcriptional repression by p53 involves molecular interactions distinct from those with the TATA box binding protein. Nucleic Acids Res. 24, 4281-4288
41. Seto, E., Usheva, A., Zambetti, G. P., Momand, J., Horikoshi, N., Weinmann, R., Levine, A. J. and Shenk, T. (1992) Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl. Acad. Sci. U.S.A. 89, 12028-12032
42. Mazure, N. M., Nguyen, T. L. and Danan, J. L. (2001) Severe hypoxia specifically downregulates hepatocyte nuclear factor-4 gene expression in HepG2 human hepatoma cells. Tumour Biol. 22, 310-317
43. Yu, D., Wang, Z. H., Cheng, S. B., Li, H. K., Chan, H. B. and Chew, E. C. (2001) The effect of arsenic trioxide on the expression of Hsc and HNF4 in nuclear matrix proteins in HepG2 cells. Anticancer Res. 21, 2553-2559
44. Filippova, M. and Duerksen-Hughes, P. J. (2003) Inorganic and dimethylated arsenic species induce cellular p53. Chem. Res. Toxicol. 16, 423-431
45. Pluquet, O. and Hainaut, P. (2001) Genotoxic and non-genotoxic pathways of p53 induction. Cancer Lett. 174, 1-15
46. Koumenis, C., Alarcon, R., Hammond, E., Sutphin, P., Hoffman, W., Murphy, M., Derr, J., Taya, Y., Lowe, S. W., Kastan, M. and Giaccia, A. (2001) Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transaction. Mol. Cell Biol. 21, 1297-1310
47. Bagchi, D., Bagchi, M., Hassoun, E. A., Kelly, J. and Stohs, S. J. (1995) Adriamycin-induced hepatic and myocardial lipid peroxidation and DNA damage, and enhanced excretion of urinary lipid metabolites in rats. Toxicology 95, 1-9
48. Ganey, P. E., Kauffman, F. C. and Thurman, R. G. (1988) Oxygen-dependent hepatotoxicity due to doxorubicin: role of reducing equivalent supply in perfused rat liver. Mol. Pharmacol. 34, 695-701
49. Kalender, Y., Yel, M. and Kalender, S. (2005) Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats. The effects of vitamin E and catechin. Toxicology 209, 39-45
50. Kimura, T., Fujita, I., Itoh, N., Muto, N., Nakanishi, T., Takahashi, K., Azuma, J. and Tanaka, K. (2000) Metallothionein acts as a cytoprotectant against doxorubicin toxicity. J. Pharmacol. Exp. Ther. 292, 299-302
51. Jaeschke, H., Gores, G. J., Cederbaum, A. I., Hinson, J. A., Pessayre, D. and Lemasters, J. J. (2002) Mechanisms of hepatotoxicity. Toxicol. Sci. 65, 166-176
52. Schafer, T., Scheuer, C., Roemer, K., Menger, M. D. and Vollmar, B. (2003) Inhibition of p53 protects liver tissue against endotoxin-induced apoptotic and necrotic cell death. FASEB J. 17, 660-367
53. Sola, S., Ma, X., Castro, R. E., Kren, B. T., Steer, C. J. and Rodrigues, C. M. (2003) Ursodeoxycholic acid modulates E2F-1 and p53 expression through a caspase-independent mechanism in transforming growth factor β1-induced apoptosis of rat hepatocytes. J. Biol. Chem. 278, 48831-48838
54. Yahagi, N., Shimano, H., Matsuzaka, T., Sekiya, M., Najima, Y., Okazaki, S., Okazaki, H., Tamura, Y., Iizuka, Y., Inoue, N. et al. (2004) p53 involvement in the pathogenesis of fatty liver disease. J. Biol. Chem. 279, 20571-20575
55. Hayhurst, G. P., Lee, Y. H., Lambert, G., Ward, J. M. and Gonzalez, F. J. (2001) Hepatocyte nuclear factor 4α (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol. Cell Biol. 21, 1393-1403
56. Li, J., Ning, G. and Duncan, S. A. (2000) Mammalian hepatocyte differentiation requires the transcription factor HNF4α. Genes Dev. 14, 464-474
57. Spath, G. F. and Weiss, M. C. (1997) Hepatocyte nuclear factor 4 expression overcomes repression of the hepatic phenotype in dedifferentiated hepatoma cells. Mol. Cell Biol. 17, 1913-1922